/PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the 2010 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in
New York City
, to be held
September 20-22, 2010
President and CEO
Tina S. Nova
, Ph.D., and
, EVP and COO of Genoptix, will present at the conference on
Tuesday, September 21, 2010
, when they will provide an overview of the Company's specialized diagnostic laboratory services business, growth strategies and financial performance.
The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Genoptix website at
. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. An audio replay will be available for 30 days following the initial presentation webcast.
About Genoptix, Inc.
Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer.
Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in
. For more information, please visit
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE Genoptix, Inc.